Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) EBT (2020 - 2023)

Historic EBT for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$21.0 million.

  • Terns Pharmaceuticals' EBT fell 3349.43% to -$21.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.0 million, marking a year-over-year decrease of 4946.53%. This contributed to the annual value of -$89.0 million for FY2024, which is 111.87% up from last year.
  • Terns Pharmaceuticals' EBT amounted to -$21.0 million in Q4 2023, which was down 3349.43% from -$29.7 million recorded in Q3 2023.
  • In the past 5 years, Terns Pharmaceuticals' EBT registered a high of -$9.2 million during Q1 2020, and its lowest value of -$29.7 million during Q3 2023.
  • In the last 4 years, Terns Pharmaceuticals' EBT had a median value of -$13.8 million in 2021 and averaged -$15.1 million.
  • In the last 5 years, Terns Pharmaceuticals' EBT tumbled by 283.75% in 2021 and then crashed by 7676.56% in 2023.
  • Over the past 4 years, Terns Pharmaceuticals' EBT (Quarter) stood at -$10.4 million in 2020, then crashed by 33.64% to -$13.9 million in 2021, then dropped by 13.29% to -$15.7 million in 2022, then tumbled by 33.49% to -$21.0 million in 2023.
  • Its last three reported values are -$21.0 million in Q4 2023, -$29.7 million for Q3 2023, and -$17.8 million during Q2 2023.